Meeting
2016 Gastrointestinal Cancers Symposium
Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience.
Authors
Manojkumar Bupathi
The Ohio State University, James Cancer Center, Columubs, OH
Manojkumar Bupathi , Daniel H. Ahn , Kristen Keon Ciombor , Christina Sing-Ying Wu , Sameh Mikhail , Richard M. Goldberg , Anne M. Noonan , Julie Stephens , Josh Reardon , John L. Hays , Tanios S. Bekaii-Saab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 215)
DOI
10.1200/jco.2016.34.4_suppl.215
Abstract #
215
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
First Author: Bert H. O'Neil
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2021 Gastrointestinal Cancers Symposium
Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.
First Author: Caleb J Smith